Watch: CNN’s Chief Medical Correspondent Dr. Sanjay Gupta speaks with our CEO Michael Curtis about the future of organ transplantation.

Our EGEN™ Platform

Our goal is to create an unlimited supply of safe and effective HuCo™ organs and cells for xenotransplantation. Our eGenesis Genome Engineering and Production (EGEN™) Platform leverages advances in gene editing technologies to address the historical challenges of xenotransplantation: risk of cross species infection and graft rejection.

We inactivate all endogenous retrovirus sequences within the porcine genome, which prevents the virus from being passed from pig to human, and use biosecure, pathogen-free animal production processes to address the risk of transmission of other viruses.

Additionally, we deploy multiplex gene editing to comprehensively address the multiple mechanisms of immune-mediated rejection of the transplanted organ. The goal of these proprietary genetic changes are to reduce inflammation and prevent the organ or cells from being identified as foreign by the human immune system.

With leading medical institutions and collaborators, we are working to advance the development of organs and cells to address the global need and save and enhance the lives of patients around the world.

Developing human-compatible organs and tissues

Multiplex Gene Editing

Multiplex gene editing allows multiple precise genetic modifications to be made simultaneously. The DNA sequence that we deliver to porcine cells is called the genetic payload. Our genetic payloads adjust the genome in three ways:

EGenesis OurSolution 211021 V2 800px Web
EGenesis MultiplexGeneEditingIcons 20210128 KnockOut

Knock outs

Porcine genes that might interact unfavorably with the human immune system are inactivated.

EGenesis MultiplexGeneEditingIcons 20210128 KnockIn GeneInsertion

Gene insertions

Human genes are introduced to reduce the likelihood of rejection.

EGenesis PrecisionGeneIntegration 211021 V4 800px Web
The genetic payload is inserted into the porcine genome by utilizing site-specific insertion that allows for a high degree of control.

Precise Genetic Integration

We use site-directed integration for an unprecedented level of control, which we believe is necessary for a successful human-compatible organ. With our genetic payloads and site-directed integration, we can determine:

  • The sequences added, subtracted, or modified
  • The properties and quantities of gene products produced in each cell
  • The exact location at which the payload genes integrate into the genome

 

Process Control and Verification

Once the genetic changes have been made to porcine cells, we isolate and grow the modified cells using a technique called clonal cell isolation. We verify that the correct genetic changes have been made through experimental testing in our laboratories.

Organ Production

Donor organs are produced in specialized facilities to ensure safety and consistency. As we advance our products to the clinical stage of development, we will scale-up production in compliance with all relevant regulatory authorities.

Our Vision

At eGenesis, we believe that xenotransplantation has the potential to transform the treatment of organ failure by eliminating waitlist mortality. We believe that our gene-editing platform will eventually reduce or eliminate the burden of post-transplant immunosuppression. We believe that one day, failing organs will be replaced with the same predictability and success seen with hip and knee replacement today.